News | Focused Ultrasound Therapy | September 18, 2017

Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy

Dual-arm study of 12 patients will assess efficacy of combining therapies to improve outcomes and reduce adverse events for metastatic breast cancer patients

Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy

September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School of Medicine, recently discussed the rationale and design of the first clinical trial combining Theraclion’s Echotherapy with the checkpoint inhibitor pembrolizumab in women with metastatic breast cancer.

Breast cancer is one of the most common malignancies with approximately 250,000 new cases expected in the U.S. in 2017. One in eight women will be diagnosed with breast cancer in their lifetimes. It is the second leading cause of death from cancer with approximately 40,000 annual deaths. Although diagnosis, treatment and survival has improved, advanced stage IV metastatic disease remains a significant challenge, with no curative therapies and a 22 percent five-year survival rate. Although immune-oncology approaches have revolutionized treatment for several cancers, such as lung cancer and melanoma, breast cancer has been resistant to immune-oncology approaches, according to Brenin, chief of breast surgery at UVA School of Medicine. The immune system does not mount an immune response against most breast cancers as tumor cells are not recognized as foreign.

Brenin’s key points included:

  • Echotherapy, also known as high intensity focused ultrasound (HIFU), induced localized tissue heating and disruption at the treatment focal point, with minimum impact on surrounding structures. Studies demonstrate that it is very well tolerated and efficacious in non-invasively removing lesions;
  • Studies have demonstrated that HIFU treatment induces an immune system response with significant increases in immune cells;
  • Pembrolizumab is able to induce an immune response to some breast cancers and HIFU is able to induce an immune response in most tumors, but not enough on its own to be curative. The rationale for the clinical study is that the combination might be more effective. HIFU facilitates infiltration of T-cells and Pembrolizumab blocks PD-1 receptors on cytotoxic T-cells greatly up-regulating the T-cell response to the breast cancer cells;
  • The clinical trial is expected to begin patient accrual at UVA in October 2017, and will be a two-arm study of 12 patients. Patients in Arm A will be treated with pembrolizumab first followed by HIFU treatment; Arm B will be the reverse. Primary objectives are to assess the adverse event profile of pembrolizumab and focused ultrasound therapy in patients with metastatic breast cancer, and to determine whether the addition of pembrolizumab to focused ultrasound increases the proportion of CD8+ tumor infiltrating lymphocytes (ratio CD8+/CD4+) in the primary ablation zone; and
  • Secondary objectives are to compare CD8+ T-cell responses at peri-ablation zones when pembrolizumab is given before or after HIFU, to evaluate clinical responses at local and distant metastatic sites by CT (computed tomography) scan and to evaluate progression free and overall survival.

For more information: www.theraclion.com

Related Content

Breast Cancer Follow-up Imaging Varies Widely
News | Breast Imaging | July 13, 2018
July 13, 2018 — Follow-up imaging for women...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Invision Diagnostics Installs VolparaEnterprise Software to Enhance Mammography Image Quality
News | Mammography | July 11, 2018
Invision Diagnostics, a provider of mobile mammography services across North and South Carolina, announced that it is...
Breast Cancer Studies Ignore Race, Socioeconomic Factors
News | Women's Health | July 11, 2018
A new commentary appearing in the July issue of Cancer Causes & Control points to evidence that social factors help...
High-Strength MRI May Release Mercury from Amalgam Dental Fillings
News | Magnetic Resonance Imaging (MRI) | July 05, 2018
Exposure to ultra-high-strength magnetic resonance imaging (MRI) may release toxic mercury from amalgam fillings in...
Jeffrey Hoffmeister, M.D.

Jeffrey Hoffmeister, M.D.

Feature | Breast Imaging | July 05, 2018 | By Jeffrey Hoffmeister, M.D.
When women reach age 40, an annual mammogram becomes a necessary part of their healthcare ritual — regardless if they...
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
Norwegian Study Confirms Higher Cancer Rate in Women with Dense Breast Tissue
News | Breast Density | July 02, 2018
A large Norwegian study using automated breast density measurements found that women with mammographically dense breast...
3-D Imaging and Computer Modeling Capture Breast Duct Development

An image of a developing mammary duct. Image courtesy of Andrew Ewald.

News | Breast Imaging | June 28, 2018
A team of biologists has joined up with civil engineers to create what is believed to be the first 3-D computer model...
Overlay Init